Kelly Louise Morrison
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
3 flagsRep. Morrison sold $15,001-$50,000 in $TMO on 2025-08-19 — 22 days before the RESULTS Act (HR5269) was introduced, which aims to stabilize Medicare reimbursement rates for clinical diagnostic laboratory tests.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $15K-$50K | $255.88 | — | — | Aug 19, 2025 |
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $15K-$50K | $255.88 | — | — | Aug 19, 2025 |
| PARTIAL SELL | $TMO | Thermo Fisher Scientific Inc Common Stock | $15K-$50K | $498.29 | — | — | Aug 19, 2025 |
| PARTIAL SELL | $TMO | Thermo Fisher Scientific Inc Common Stock | $15K-$50K | $498.29 | — | — | Aug 19, 2025 |
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $1K-$15K | $255.88 | — | — | Aug 19, 2025 |
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $1K-$15K | $255.88 | — | — | Aug 19, 2025 |
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $1K-$15K | $255.88 | — | — | Aug 19, 2025 |
| PARTIAL SELL | $JNJ | Johnson & Johnson Common Stock | $1K-$15K | $177.80 | — | — | Aug 19, 2025 |
| PARTIAL SELL | $TMO | Thermo Fisher Scientific Inc Common Stock | $1K-$15K | $498.29 | — | — | Aug 19, 2025 |
| PARTIAL SELL | $TMO | Thermo Fisher Scientific Inc Common Stock | $1K-$15K | $498.29 | — | — | Aug 19, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act (HR5127) mandates zero-cost coverage of HIV prevention drugs and associated lab monitoring across all US insurance programs. This early-stage bipartisan bill creates direct volume upside for Gilead ($GILD) on branded PrEP, Viatris ($VTRS) on generic PrEP, and Labcorp ($LH) on mandatory diagnostic services. Merck ($MRK) is excluded from the causal chain because its islatravir candidate is not FDA-approved and the bill only covers approved drugs.
RESULTS Act
The RESULTS Act (HR5269) is an early-stage bill aiming to stabilize Medicare reimbursement for clinical diagnostic lab tests by improving data accuracy. It has 77 cosponsors and a companion bill in the Senate but remains in committee with no near-term market impact. Real market data shows LH at $259 and DGX at $190.19, both down ~3% over 30 days, reflecting sector headwinds unrelated to this procedural legislation.
Biosimilar Red Tape Elimination Act
The Biosimilar Red Tape Elimination Act (HR5526) would remove FDA interchangeability study requirements, speeding market entry for $VTRS and $TEVA biosimilars. Market data shows $VTRS +11.55% and $TEVA +17.73% over 30 days, consistent with investors pricing in this regulatory catalyst. Innovators $AMGN (-2.11% 30-day), $JNJ (-5.95%), and $BIIB (+4.18%) face structural margin pressure as pharmacy-level substitution becomes automatic upon biosimilar approval.
Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act
H.R. 5355 is an early-stage authorization bill with no appropriations attached, requiring HHS rulemaking to promote newborn liver disease screening. Revenue impact for diagnostic companies is structurally contingent on future funding and state adoption. Current market data shows diagnostic stocks in a short-term downtrend, with the bill too nascent to influence price action.
ACCENTURE FEDERAL SERVICES LLC: $12.0M Department of Justice Contract
Accenture Federal Services LLC, a subsidiary of Accenture plc ($ACN), secured a $12.0 million BPA Call from the FBI for EPAS Services. This contract represents a negligible portion of Accenture's annual revenue and is a routine award for IT services.
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.
HR5917 is an early-stage procedural bill authorizing the President to extend normal trade relations to most countries by waiving the Jackson-Vanik amendment. It authorizes no funding and changes no current tariff levels. Real market data shows $WMT at $130.81 near its 52-week high, with a 30-day gain of 5.25%, and $AAPL up 8.8% in 30 days—indicating that favorable trade expectations are already priced in. The bill faces a long legislative path with no near-term market impact.
Protecting Free Vaccines Act of 2025
The Protecting Free Vaccines Act of 2025 is an early-stage bill (S.2857) that codifies existing ACIP vaccine coverage mandates through 2030 without expanding coverage, creating new funding, or changing market dynamics. The bill's impact on vaccine manufacturers and insurers is neutral: it removes regulatory uncertainty but provides no growth catalyst. All S&P 500 stocks covered have been declining over the past 30 days, with MRNA down 13.49% in the last week alone. This bill does not alter those trends.
Foreign Robocall Elimination Act
The Foreign Robocall Elimination Act (S. 2666) is a procedural authorization bill establishing an interagency taskforce on unlawful robocalls. No new funding is authorized, but the bill mandates increased cybersecurity and analytics investment by telecom carriers. Pure-play cybersecurity firms $CRWD, $PANW, and $FTNT have seen strong 30-day gains of +12.54%, +9.86%, and +2.13% respectively, reflecting broad sector momentum. The bill is still awaiting floor action after passing committee, adding timing uncertainty.
Protecting Free Vaccines Act
The Protecting Free Vaccines Act (HR5448) is an early-stage House bill that would mandate zero-cost-sharing coverage for ACIP-recommended vaccines across Medicare, Medicaid, CHIP, and private insurance until 2030. Vaccine manufacturers like Pfizer and Moderna are structurally positioned to benefit from increased utilization, while health insurers like UnitedHealth face higher claims costs. CVS has mixed exposure as both insurer (Aetna) and vaccine administrator (CVS Pharmacy). The bill is referred to three committees with 72 cosponsors and has a Senate companion bill (S2857), but a long legislative path remains.
Ensuring Patient Access to Critical Breakthrough Products Act
HR5343 would force Medicare to provide immediate 4-year coverage for FDA breakthrough devices, directly benefiting large medical device manufacturers by eliminating the current 1-3 year coverage lag. The bill passed the Ways & Means committee 37-3 but awaits floor action. Despite bearish recent price action (MDT -8.2%, ABT -11%, BDX -7.3% in 30 days), this bill represents a structural catalyst for device revenue acceleration.
Other Filings by Kelly Louise Morrison
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.